Insmed CEO reveals Japan patient population exceeds US market for lung disease

Core Insights - Insmed's CEO revealed that Japan has a larger patient population for MAC lung disease than the entire United States, significantly impacting the investment thesis for the company [5]. Market Expansion - Insmed announced positive Phase 3b results for ARIKAYCE, which could expand its addressable market from 30,000 to over 200,000 patients, with a supplemental FDA filing planned for the second half of 2026 [2][9]. - Japan contributed over 25% of ARIKAYCE's global revenues and experienced a growth rate of 40% in 2025, outpacing U.S. growth of 7.7% to 14.1% [2][10]. Financial Projections - Insmed's dual-blockbuster structure includes BRINSUPRI, projected to generate over $1 billion in 2026, and ARIKAYCE, expected to generate between $450 million and $470 million [3][12]. - The full commercial impact of the label expansion for ARIKAYCE is anticipated to materialize in 2027 [9]. Competitive Landscape - The ENCORE Phase 3b trial demonstrated positive results, meeting all primary and secondary endpoints, which enhances the long-term outlook for ARIKAYCE [8][13]. - The growth rates in Japan (48.3% in Q1 2025 and 45.3% in Q2 2025) indicate that the Japanese market is not a secondary market but a significant opportunity for Insmed [10][11].